Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, et al
Do my health conditions require in-person monitoring rather than telehealth-only care
The glucagon component introduces new considerations, but serious adverse events attributable specifically to glucagon receptor activation were rare in clinical trials
Following in vitro tests, compound 57 (Figure 7) was shown to be the most potent DPP-4 inhibitor, with an IC 50 of 0.87 nM
Currently, outside of clinical trials, retatrutide is accessed in grey-market/research-peptide channels as a lyophilized powder requiring reconstitution with bacteriostatic water and delivery via insulin syringe
But we should be equally concerned that this new and effective treatment reduces disparities between the haves and have-nots.